Cas:522-57-6 (6,7-dimethoxyisoquinolin-1-yl)-(3,4-dimethoxyphenyl)methanone manufacturer & supplier

Chemical Name:(6,7-dimethoxyisoquinolin-1-yl)-(3,4-dimethoxyphenyl)methanone

CAS.NO:522-57-6

Synonyms:Xanthaline;6,7-Dimethoxy-1-veratroylisoquinoline;Papaveraldin;Papaveraldine;(6,7-Dimethoxy-1-isoquinolyl) (3,4-dimethoxyphenyl) ketone

Molecular Formula:C₂₀H₁₉NO₅

Molecular Weight:353.36900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:537.9ºC at 760mmHg

Density:1.214g/cm3

Index of Refraction:1.593

PSA:66.88000

Exact Mass:353.12600

LogP:3.50020

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Xanthaline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(6,7-Dimethoxy-1-isoquinolyl) (3,4-dimethoxyphenyl) ketone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Papaveraldin Use and application,Xanthaline technical grade,usp/ep/jp grade.

Related News: At the same time, because the profits of a single variety of characteristic APIs do not have long-term growth, companies need more product reserves. (6,7-dimethoxyisoquinolin-1-yl)-(3,4-dimethoxyphenyl)methanone manufacturer Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies. (6,7-dimethoxyisoquinolin-1-yl)-(3,4-dimethoxyphenyl)methanone supplier Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies. (6,7-dimethoxyisoquinolin-1-yl)-(3,4-dimethoxyphenyl)methanone vendor AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. (6,7-dimethoxyisoquinolin-1-yl)-(3,4-dimethoxyphenyl)methanone factory Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies.